We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Sicor and BioGeneriX to Develop Generic Biopharmaceuticals

By Biotechdaily staff writers
Posted on 31 Jul 2003
An agreement to jointly develop and market a recombinant protein pharmaceutical has been announced by Sicor, Inc. More...
(Irvine, CA, USA; www.sicor.com) and BioGeneriX AG (Mannheim, Germany; www.biogenerix.com).

The pharmaceutical will be manufactured and produced by Sicor and marketed in Europe by BioGeneriX's parent company (ratiopharm), following regulatory approval. BioGeneriX will receive a royalty on Sicor's sales in North and Central America. Financial terms were not disclosed.

Sicor is a multinational pharmaceutical company focused on generic injectable pharmaceuticals and generic biopharmaceuticals, concentrating on products and technologies that present significant barriers to entry or that offer first-to-market opportunities. BioGeneriX specializes in the development of biopharmaceutical drugs with known mode of actions and established markets for ratiopharm and other global partners.

"This collaboration provides access to European markets through the BioGeneriX clinical development program and ratiopharm's sales force while simultaneously giving Sicor the potential to expedite its entry into North American biopharmaceutical markets,” said Marvin Samson, president and CEO of Sicor.





Related Links:
Sicor
BioGeneriX

New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Thyroid Test
Anti-Thyroid EIA Test
New
Multi-Chamber Washer-Disinfector
WD 390
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The device contains specific antibodies that capture the primary biomarker of pancreatic cancer. The binding of these antibodies alters the distribution of electrical charges on the electrode surface. The sensor then translates this variation into a measurable capacitance signal (photo courtesy of Gabriella Soares / IFSC-USP)

Rapid Biosensor Detects Pancreatic Cancer Biomarker for Early Detection

Pancreatic cancer is frequently identified only after it has progressed because early disease is typically asymptomatic, and survival remains extremely poor once advanced. Conventional laboratory assays... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.